Telemedicine Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
East China University of Science & Technology, People's Republic of China
New data from the People's Republic of China, Japan and United Kingdom lluminates research in cancer treatment
September 13th, 2006
Data on cancer treatment are outlined in reports from the People's Republic of China, Japan and United Kingdom. Study 1: Investigators have constructed and purified an HIV-TAT-survivin (T34A) mutant. Scientists in China report, "As a novel member of the IAP family, survivin was observed to express in the most common human cancers. Anticancer therapy targeting survivin has drawn considerable attention. This report presented firstly construction of recombinant plasmid pRSET-B-TAT-survivin (T34A), expression in Escherichia coli, purification, renaturation, and bioactivity. The cDNA encoding survivin was cloned by RTPCR from breast cancer cell...
Source: Telemedicine Business Week (2006-09-13)
|
